AbbVie (NYSE:ABBV) Stock Jumps 1.6% - Should You Buy?

Key Points

• AbbVie shares rose 1.6% to about $280.87, supported by expectations that Skyrizi and Rinvoq will continue driving growth and offsetting Humira sales erosion.
• Long-term clinical data and broadly positive analyst coverage bolster the outlook: AbbVie has a consensus “Moderate Buy” rating, with an average price target of $277.18.
• Risks include elevated valuation, increasing immunology competition and a declining dividend yield. The stock trades at roughly 79 times earnings, while its quarterly dividend is $1.73, yielding about 2.5%.

AbbVie Inc. (NYSE:ABBV - Get Free Report) shares rose 1.6% during mid-day trading on Monday. The company traded as high as $281.30 and last traded at $280.8740. Approximately 5,493,473 shares traded hands during trading, a decline of 14% from the average daily volume of 6,414,131 shares. The stock had previously closed at $276.47.

Key AbbVie News

Here are the key news stories impacting AbbVie this week:

• Positive Sentiment: Skyrizi and Rinvoq remain the primary growth engines. Analysts expect the two drugs to drive third-quarter revenue growth and offset continuing erosion in Humira sales. However, increasing competition in immunology remains a consideration. Will Skyrizi & Rinvoq Drive AbbVie's Top-Line Growth in Q3?
• Positive Sentiment: New clinical data support AbbVie’s leading immunology portfolio. The company highlighted long-term SKYRIZI and RINVOQ findings at ACG 2026, reinforcing confidence in the drugs’ durability and commercial potential. AbbVie Highlights Long-Term SKYRIZI, RINVOQ Data Findings At ACG 2026
• Positive Sentiment: Analyst sentiment is supportive. Guggenheim reaffirmed a “Buy” rating, while a separate report noted that AbbVie’s accelerating growth, recent acquisition and fresh FDA approval could support its next major revenue opportunity. Wall Street’s cited targets range from a $246 bearish case to a $297 bullish case. AbbVie Stock Rating Reaffirmed as Buy by Guggenheim
• Neutral Sentiment: Sector M&A activity is improving. Rising pharmaceutical deal activity is supporting broader biotechnology sentiment as drugmakers seek replacement products ahead of patent expirations, though this is an industry tailwind rather than a specific new catalyst for ABBV. Biotech's Rebound Reality: Surging M&A Deals Meet Deep Retail Skepticism
• Negative Sentiment: Valuation and income concerns could limit upside. ABBV’s strong share-price appreciation has pushed its dividend yield to its lowest level since 2018, while its elevated valuation leaves the stock sensitive to slower-than-expected Skyrizi and Rinvoq growth, Humira erosion or additional competition.

Wall Street Analyst Weigh In

ABBV has been the topic of a number of research analyst reports. Wolfe Research upgraded shares of AbbVie from a "peer perform" rating to an "outperform" rating and upped their price target for the stock from $235.00 to $300.00 in a report on Thursday, August 13th. Argus lifted their price objective on shares of AbbVie from $250.00 to $270.00 in a report on Tuesday, August 4th. Royal Bank Of Canada lifted their price objective on shares of AbbVie from $260.00 to $280.00 and gave the company an "outperform" rating in a report on Friday, July 10th. Wells Fargo & Company boosted their price objective on shares of AbbVie from $295.00 to $300.00 and gave the company an "overweight" rating in a research report on Monday, August 17th. Finally, Bank of America reissued a "buy" rating on shares of AbbVie in a research report on Tuesday, September 8th. One research analyst has rated the stock with a Strong Buy rating, twenty-three have assigned a Buy rating and six have issued a Hold rating to the company. According to data from MarketBeat, AbbVie currently has a consensus rating of "Moderate Buy" and an average target price of $277.18.

AbbVie Stock Performance

The firm has a fifty day simple moving average of $259.06 and a 200 day simple moving average of $236.86. The company has a market capitalization of $496.25 billion, a PE ratio of 79.34, a P/E/G ratio of 1.26 and a beta of 0.24.

AbbVie (NYSE:ABBV - Get Free Report) last issued its earnings results on Friday, July 31st. The company reported $3.65 earnings per share for the quarter, topping the consensus estimate of $3.61 by $0.04. AbbVie had a negative return on equity of 422.07% and a net margin of 9.80%. The business had revenue of $16.99 billion during the quarter, compared to analysts' expectations of $16.80 billion. During the same period in the prior year, the business earned $2.97 EPS. The business's revenue for the quarter was up 10.2% compared to the same quarter last year. AbbVie has set its Q3 2026 guidance at 3.840-3.880 EPS. Research analysts expect that AbbVie Inc. will post 13.94 EPS for the current fiscal year.

AbbVie Dividend Announcement

The company also recently disclosed a quarterly dividend, which will be paid on Monday, November 16th. Investors of record on Thursday, October 15th will be issued a $1.73 dividend. This represents a $6.92 annualized dividend and a dividend yield of 2.5%. The ex-dividend date is Thursday, October 15th. AbbVie's payout ratio is presently 195.48%.

Insiders Place Their Bets

In related news, EVP Nicholas Donoghoe sold 32,710 shares of the company's stock in a transaction dated Friday, August 14th. The shares were sold at an average price of $250.00, for a total value of $8,177,500.00. Following the completion of the sale, the executive vice president directly owned 74,430 shares of the company's stock, valued at $18,607,500. This represents a 30.53% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. 0.06% of the stock is currently owned by company insiders.

Institutional Inflows and Outflows

Institutional investors have recently added to or reduced their stakes in the business. Corient Private Wealth LP purchased a new position in shares of AbbVie in the second quarter valued at approximately $559,736,000. Legal & General Group Plc acquired a new stake in shares of AbbVie in the second quarter worth approximately $2,905,952,000. Jupiter Topco LLC acquired a new stake in shares of AbbVie in the second quarter worth approximately $1,560,354,000. Diamant Asset Management Inc. increased its position in shares of AbbVie by 21,649.0% during the first quarter. Diamant Asset Management Inc. now owns 3,671,231 shares of the company's stock worth $798,456,000 after purchasing an additional 3,654,351 shares in the last quarter. Finally, Canada Pension Plan Investment Board purchased a new stake in shares of AbbVie during the second quarter worth approximately $817,473,000. Hedge funds and other institutional investors own 70.23% of the company's stock.

About AbbVie

AbbVie Inc is a global biopharmaceutical company that develops, manufactures and markets medicines for a range of serious and chronic health conditions. Its portfolio spans immunology, oncology, neuroscience, eye care, aesthetics, gastroenterology and women's health.

The company's products include the immunology medicines Skyrizi and Rinvoq; neuroscience treatments such as Vraylar, Ubrelvy and Qulipta; and oncology medicines including Imbruvica and Venclexta. AbbVie also markets Botox Cosmetic and Botox Therapeutic, as well as other products for aesthetics, eye care and specialty care.

AbbVie was established in 2013 as an independent, publicly traded company following its separation from Abbott Laboratories.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.